LSP-249
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell[1].
Product Specifications
CAS Number
1801253-04-2
UNSPSC
12352005
Target
Kallikrein
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lsp-249.html
Concentration
10mM
Purity
99.05
Solubility
DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CC(CC2=CC=C3N=CC(Cl)=CC3=C2)=NC=C1)NCC4=C(C)C=C(N)N=C4C
Molecular Formula
C24H22ClN5O
Molecular Weight
431.92
References & Citations
[1]Andrew Mcdonald, et al. Therapeutic inhibitory compounds. Patent. WO2016011209A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bsm-61665R-RBITC-TR 20 µL
Macro H2A.1 Recombinant Antibody, RBITC Conjugated
Sign In for Pricing
View Details 